Molecular determinants of non-specific recognition of δ, μ, and κ opioid receptors

Abstract Identification of the molecular determinants of recognition common to all three opioid receptors embedded in a single three-dimensional (3D) non-specific recognition pharmacophore has been carried out. The working hypothesis that underlies the computational study reported here is that ligands that bind with significant affinity to all three cloned opioid receptors, δ, μ, and κ, but with different combinations of activation and inhibition properties at these receptors, could be promising behaviorally selective analgesics with diminished side effects. The study presented here represents the first step towards the rational design of such therapeutic agents. The common 3D pharmacophore developed for recognition of δ, μ, and κ opioid receptors was based on the receptor affinities determined for 23 different opioid ligands that display no specificity for any of the receptor subtypes. The pharmacophore centers identified are a protonated amine, two hydrophobic groups, and the centroid of an aromatic group in a geometric arrangement common to all 23, non-specific, opioid ligands studied. Using this three-dimensional pharmacophore as a query for searching 3D structural databases, novel compounds potentially involved in non-specific recognition of δ, μ, and κ opioid receptors were retrieved. These compounds can be valuable candidates for novel behaviorally selective analgesics with diminished or no side effects, and thus with potential therapeutic usefulness.

[1]  G. Loew,et al.  Pharmacological profiles of fentanyl analogs at μ, δ and κ opiate receptors , 1992 .

[2]  R. H. Woudenberg,et al.  Chemistry of opium alkaloids. Part 44: synthesis and opioid receptor binding profile of substituted ethenoisomorphinans and ethenomorphinans. , 1999, Bioorganic & medicinal chemistry.

[3]  R. Edwards,et al.  Cloning of a delta opioid receptor by functional expression. , 1992, Science.

[4]  B. Kieffer,et al.  A molecular basis for opiate action. , 1998, Essays in biochemistry.

[5]  N. Blaton,et al.  Structural studies of substituted 6,7-benzomorphan compounds. VI. (−)-(1R,5R,9R,13R)-2'-Hydroxy-5,9α-dimethyl-2-(tetrahydrofurfuryl)-6,7-benzomorphan and (−)-(1R,5R,9R,13S)-2'-hydroxy-5,9-dimethyl-2-(tetrahydrofurfuryl)-6,7-benzomorphan tartrate monohydrate , 1982 .

[6]  D. Ferguson,et al.  Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor. , 2000, Journal of medicinal chemistry.

[7]  G H Loew,et al.  Evidence for mu1-opioid receptor involvement in fentanyl-mediated respiratory depression. , 1996, European journal of pharmacology.

[8]  Lei Yu,et al.  Molecular cloning and functional expression of a mu opioid receptor from rat brain , 1994, Regulatory Peptides.

[9]  Judith L. Flippen-Anderson,et al.  X-Ray crystal structures of potent opioid receptor ligands: etonitazene, cis-(+)-3-methylfentanyl, etorphine, diprenorphine, and buprenorphine , 1994 .

[10]  L. Bare,et al.  Isolation of a Human κ Opioid Receptor cDNA from Placenta , 1994 .

[11]  A. Kastin,et al.  Opiate tolerance and dependence: receptors, G-proteins, and antiopiates , 1998, Peptides.

[12]  Marta Filizola,et al.  Molecular modeling study of the differential ligand–receptor interaction at the μ, δ and κ opioid receptors , 1999, J. Comput. Aided Mol. Des..

[13]  A Ulloa-Aguirre,et al.  Structure-activity relationships of G protein-coupled receptors. , 1999, Archives of medical research.

[14]  V. Ananthanarayanan,et al.  Homology models of mu-opioid receptor with organic and inorganic cations at conserved aspartates in the second and third transmembrane domains. , 2000, Archives of biochemistry and biophysics.

[15]  H Weinstein,et al.  Comparative modeling and molecular dynamics studies of the delta, kappa and mu opioid receptors. , 1997, Protein engineering.

[16]  Gilda H. Loew,et al.  Thermodynamics of ligand binding to the cloned δ-opioid receptor , 1996 .

[17]  Jonas Boström,et al.  Conformational energy penalties of protein-bound ligands , 1998, J. Comput. Aided Mol. Des..

[18]  Hugo O. Villar,et al.  Characterization of low-energy conformational domains for Met-enkephalin , 1992, J. Comput. Aided Mol. Des..

[19]  M. Nishi,et al.  Primary structures and expression from cDNAs of rat opioid receptor δ‐and μ‐subtypes , 1993 .

[20]  Juan J. Perez,et al.  Characterization of the bioactive form of linear peptide antagonists at the δ‐opioid receptor , 1996 .

[21]  G. Loew,et al.  A 3D model of the δ opioid receptor and ligand-receptor complexes , 1996 .

[22]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[23]  Marta Filizola,et al.  3D modeling, ligand binding and activation studies of the cloned mouse δ, μ and κ opioid receptors , 1999 .

[24]  G. Uhl,et al.  Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. , 1994, FEBS letters.

[25]  H. Kubota,et al.  Synthesis and biological activity of 3-substituted 3-desoxynaltrindole derivatives. , 1998, Bioorganic & medicinal chemistry letters.

[26]  U. Gether.  Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. , 2000, Endocrine reviews.

[27]  H. Villar,et al.  Characterization of the bioactive form and molecular determinants of recognition of cyclic enkephalin peptides at the δ‐opioid receptor , 1993, Biopolymers.

[28]  A. Lomize,et al.  Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints. , 1998, Biophysical journal.

[29]  Yvonne C. Martin,et al.  A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists , 1993, J. Comput. Aided Mol. Des..

[30]  Ping Huang,et al.  Development of a common 3D pharmacophore for δ-opioid recognition from peptides and non-peptides using a novel computer program , 1997, J. Comput. Aided Mol. Des..

[31]  G. Loew,et al.  Opioid agonists binding and responses in SH-SY5Y cells. , 1992, Life sciences.

[32]  C L Brooks,et al.  Do active site conformations of small ligands correspond to low free-energy solution structures? , 1998, Journal of computer-aided molecular design.

[33]  Michal Hušák,et al.  The Crystal and Molecular Structure of Butorphanol Hydrogen Tartrate , 1994 .

[34]  G H Loew,et al.  Molecular determinants of mu receptor recognition for the fentanyl class of compounds. , 1992, Molecular pharmacology.

[35]  H. Loh,et al.  Regulation of opioid receptor activities. , 1999, The Journal of pharmacology and experimental therapeutics.